10-KPeriod: FY2022

AGILENT TECHNOLOGIES, INC. Annual Report, Year Ended Oct 31, 2022

Filed December 21, 2022For Securities:A

Summary

Agilent Technologies, Inc. (Agilent) reported strong performance for the fiscal year ended October 31, 2022, with net revenue of $6.85 billion, an increase of 8% compared to the prior year, despite navigating challenges like supply chain pressures, inflation, and a COVID-related shutdown in China. All three business segments—Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab—experienced revenue growth. The company's financial health remains robust, with significant cash on hand and a strong operating margin of 23.6%. Agilent also demonstrated a commitment to shareholder returns through substantial share repurchases and consistent dividend payments. Looking ahead, Agilent anticipates continued inflationary and logistical pressures but remains optimistic about growth opportunities across its key end markets. The company continues to invest in research and development and strategic initiatives to enhance its product and service offerings, positioning itself for sustained long-term growth in the life sciences, diagnostics, and applied chemical markets.

Financial Highlights

57 data points
Beta

Revenue

$6.85B

54.4% Gross Margin

Net Income

$1.25B

18.3% Net Margin

EPS (Diluted)

$4.18

Total Assets

$10.53B

Cash & Equivalents

$1.06B

Free Cash Flow

$1.02B

Financial Statements
Beta
Revenue$6.85B
Cost of Revenue$3.13B
Gross Profit$3.72B
R&D Expenses$467.00M
SG&A Expenses$1.64B
Operating Expenses$5.23B
Operating Income$1.62B
Interest Expense$84.00M
Net Income$1.25B
EPS (Basic)$4.19
EPS (Diluted)$4.18
Shares Outstanding (Basic)299.00M
Shares Outstanding (Diluted)300.00M

Key Highlights

  • 1Net revenue increased by 8% to $6.85 billion in fiscal year 2022, with growth reported across all business segments.
  • 2The company maintained a strong operating margin of 23.6% despite inflationary and supply chain pressures.
  • 3Agilent repurchased approximately $1.14 billion of its common stock in fiscal year 2022, demonstrating a commitment to shareholder returns.
  • 4The Life Sciences and Applied Markets segment saw a 9% revenue increase, driven by demand in pharmaceutical and chemicals and advanced materials markets.
  • 5The Diagnostics and Genomics segment grew revenue by 7%, with strong performance in nucleic acid solutions.
  • 6Agilent CrossLab services reported a 7% revenue increase, supported by contract repair, compliance, and installation services.
  • 7The company ended the fiscal year with $1.05 billion in cash and cash equivalents, indicating a healthy liquidity position.

Frequently Asked Questions

In fiscal year 2022, Agilent Technologies reported a net revenue of $6.85 billion, an increase of 8% compared to the prior year. The company experienced growth across all three of its business segments and maintained a strong operating margin of 23.6%, demonstrating resilience despite facing supply chain disruptions, inflation, and a COVID-related shutdown in China.

Agilent navigated supply chain and inflationary pressures through strategies such as targeted pricing increases and various sourcing initiatives. While these factors impacted costs, the company was able to offset them with higher sales volumes and improved gross margins in some areas.

Agilent anticipates continued inflationary and logistical pressures in fiscal year 2023 but remains optimistic about growth opportunities across its key end markets. The company plans to continue investing in research and development and strategic initiatives to expand its product and service offerings.

Agilent demonstrates its commitment to shareholder returns through a combination of consistent dividend payments and a robust share repurchase program. In fiscal year 2022, the company repurchased approximately $1.14 billion of its common stock under its 2021 repurchase program, in addition to paying out $250 million in dividends.